Zacks Research Issues Positive Estimate for GSK Earnings

GSK PLC Sponsored ADR (NYSE:GSK) – Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for shares of GSK in a report issued on Tuesday, September 2nd. Zacks Research analyst Team now expects that the pharmaceutical company will post earnings of $1.15 per share for the quarter, up from their previous estimate of $1.11. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q1 2027 earnings at $1.18 EPS and Q2 2027 earnings at $1.22 EPS.

Several other equities analysts also recently weighed in on the stock. Berenberg Bank reissued a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $37.38.

GSK Price Performance

NYSE:GSK opened at $40.41 on Thursday. GSK has a 12 month low of $31.72 and a 12 month high of $44.19. The stock has a 50 day moving average of $38.51 and a two-hundred day moving average of $38.33. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm has a market cap of $82.30 billion, a P/E ratio of 18.71, a price-to-earnings-growth ratio of 1.71 and a beta of 0.53.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. During the same period in the previous year, the business earned $0.43 EPS. GSK’s quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently made changes to their positions in GSK. Brighton Jones LLC acquired a new stake in shares of GSK during the fourth quarter valued at about $528,000. BNP Paribas Financial Markets acquired a new stake in shares of GSK during the fourth quarter valued at about $12,423,000. Bayesian Capital Management LP acquired a new stake in shares of GSK during the fourth quarter valued at about $475,000. Cary Street Partners Financial LLC acquired a new stake in shares of GSK during the fourth quarter valued at about $228,000. Finally, Crestline Management LP acquired a new stake in shares of GSK during the fourth quarter valued at about $1,047,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. GSK’s payout ratio is 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.